- Home
- ALXO vs PEPG Comparison
ALXO vs PEPG Comparison
Compare ALXO & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- PEPG
- Stock Information
- Founded
- ALXO 2015
- PEPG 2018
- Country
- ALXO United States
- PEPG United States
- Employees
- ALXO N/A
- PEPG N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- PEPG Health Care
- Exchange
- ALXO Nasdaq
- PEPG Nasdaq
- Market Cap
- ALXO 56.8M
- PEPG 45.9M
- IPO Year
- ALXO 2020
- PEPG 2022
- Fundamental
- Price
- ALXO $1.05
- PEPG $1.59
- Analyst Decision
- ALXO Strong Buy
- PEPG Buy
- Analyst Count
- ALXO 6
- PEPG 4
- Target Price
- ALXO $3.30
- PEPG $7.25
- AVG Volume (30 Days)
- ALXO 1.7M
- PEPG 365.2K
- Earning Date
- ALXO 11-06-2025
- PEPG 11-06-2025
- Dividend Yield
- ALXO N/A
- PEPG N/A
- EPS Growth
- ALXO N/A
- PEPG N/A
- EPS
- ALXO N/A
- PEPG N/A
- Revenue
- ALXO N/A
- PEPG N/A
- Revenue This Year
- ALXO N/A
- PEPG N/A
- Revenue Next Year
- ALXO N/A
- PEPG N/A
- P/E Ratio
- ALXO N/A
- PEPG N/A
- Revenue Growth
- ALXO N/A
- PEPG N/A
- 52 Week Low
- ALXO $0.40
- PEPG $0.88
- 52 Week High
- ALXO $2.36
- PEPG $10.06
- Technical
- Relative Strength Index (RSI)
- ALXO 54.14
- PEPG 65.63
- Support Level
- ALXO $1.01
- PEPG $1.35
- Resistance Level
- ALXO $1.27
- PEPG $1.85
- Average True Range (ATR)
- ALXO 0.12
- PEPG 0.13
- MACD
- ALXO -0.02
- PEPG 0.03
- Stochastic Oscillator
- ALXO 29.03
- PEPG 63.98
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.